Metalloporphyrins as therapeutic catalytic oxidoreductants in central nervous system disorders

Antioxidants and Redox Signaling

Volumn 20, Issue 15, 2014, Pages 2437-2464

  Sheng, Huaxin ^a   Chaparro, Raphael E ^a   Sasaki, Toshihiro ^a   Izutsu, Miwa ^a   Pearlstein, Robert D ^a   Tovmasyan, Artak ^a   Warner, David S ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOXIDANT; METALLOPORPHYRIN; OPIATE;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; BLOOD BRAIN BARRIER; BRAIN ARTERY ANEURYSM; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CATALYST; CENTRAL NERVOUS SYSTEM DISEASE; CEREBROVASCULAR ACCIDENT; DRUG BIOAVAILABILITY; DRUG MECHANISM; DRUG TOLERANCE; EPILEPSY; HUMAN; NEUROPATHIC PAIN; NITROSATIVE STRESS; NONHUMAN; OXIDATIVE STRESS; PAIN; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; SPINAL CORD INJURY; SYNTHESIS; TRAUMATIC BRAIN INJURY; ANIMAL; CENTRAL NERVOUS SYSTEM DISEASES; CHEMISTRY; DRUG EFFECTS; METABOLISM; OXIDATION REDUCTION REACTION;

ANIMALS; ANTIOXIDANTS; CENTRAL NERVOUS SYSTEM DISEASES; HUMANS; METALLOPORPHYRINS; OXIDATION-REDUCTION; OXIDATIVE STRESS;

EID: 84899709321     PISSN: 15230864     EISSN: 15577716     Source Type: Journal    
DOI: 10.1089/ars.2013.5413     Document Type: Review

References (228)

1. Aguiar CC, Almeida AB, Araujo PV, de Abreu RN, Chaves EM, do Vale OC, Macedo DS, Woods DJ, Fonteles MM, and Vasconcelos SM. Oxidative stress and epilepsy: literature review. Oxid Med Cell Longev 2012: 795259, 2012.
2. Aladag MA, Turkoz Y, Sahna E, Parlakpinar H, and Gul M. The attenuation of vasospasm by using a sod mimetic after experimental subarachnoidal haemorrhage in rats. Acta Neurochir (Wien) 145: 673-677, 2003.
3. Alam ZI, Jenner A, Daniel SE, Lees AJ, Cairns N, Marsden CD, Jenner P, and Halliwell B. Oxidative DNA damage in the parkinsonian brain: an apparent selective increase in 8-hydroxyguanine levels in substantia nigra. J Neurochem 69: 1196-1203, 1997.
4. Altug S, Uludag O, Tunctan B, Cakici I, Zengil H, and Abacioglu N. Biological time-dependent difference in effect of peroxynitrite demonstrated by the mouse hot plate pain model. Chronobiol Int 23: 583-591, 2006.
5. Anderson SW, Todd MM, Hindman BJ, Clarke WR, Torner JC, Tranel D, Yoo B, Weeks J, Manzel KW, and Samra S. Effects of intraoperative hypothermia on neuropsychological outcomes after intracranial aneurysm surgery. Ann Neurol 60: 518-527, 2006.
6. Arthur CR, Morton SL, Dunham LD, Keeney PM, and Bennett JP, Jr. Parkinson's disease brain mitochondria have impaired respirasome assembly, age-related increases in distribution of oxidative damage to mtDNA and no differences in heteroplasmic mtDNA mutation abundance. Mol Neurodegener 4: 37, 2009.
7. Atamna H and Frey WH, 2nd. Mechanisms of mitochondrial dysfunction and energy deficiency in Alzheimer's disease. Mitochondrion 7: 297-310, 2007.
8. Bao F, DeWitt DS, Prough DS, and Liu D. Peroxynitrite generated in the rat spinal cord induces oxidation and nitration of proteins: reduction by Mn (III) tetrakis (4-benzoic acid) porphyrin. J Neurosci Res 71: 220-227, 2003.
9. Bao F and Liu D. Hydroxyl radicals generated in the rat spinal cord at the level produced by impact injury induce cell death by necrosis and apoptosis: protection by a metalloporphyrin. Neuroscience 126: 285-295, 2004.
10. Barnum CJ and Tansey MG. Modeling neuroinflammatory pathogenesis of Parkinson's disease. Prog Brain Res 184: 113-132, 2010.
11. Batinic-Haberle I, Benov L, Spasojevic I, Hambright P, Crumbliss AL, and Fridovich I. The relationship between redox potentials, proton dissociation constants of pyrrolic nitrogens, and in vitro and in vivo superoxide dismutase activities of manganese(III) and iron(III) cationic and anionic porphyrins. Inorg Chem 38: 4011-4022, 1999.
12. Batinic-Haberle I, Reboucas JS, Benov L, and Spasojevic I. Chemistry, biology and medical effects of water soluble metalloporphyrins. In: Handbook of Porphyrin Science, edited by Kadish KM, Smith KM, and Guillard R. Singapore: World Scientific, 2011, pp. 291-393.
13. Batinic-Haberle I. Manganese porphyrins and related compounds as mimics of superoxide dismutase. Methods Enzymol 349: 223-233, 2002.
14. Batinic-Haberle I, Benov L, Spasojevic I, and Fridovich I. The ortho effect makes manganese(III) meso-tetrakis(Nmethylpyridinium- 2-yl)porphyrin a powerful and potentially useful superoxide dismutase mimic. J Biol Chem 273: 24521-24528, 1998.
15. Batinic-Haberle I, Cuzzocrea S, Reboucas JS, Ferrer-Sueta G, Mazzon E, Di Paola R, Radi R, Spasojevic I, Benov L, and Salvemini D. Pure MnTBAP selectively scavenges peroxynitrite over superoxide: comparison of pure and commercial MnTBAP samples to MnTE-2-PyP in two models of oxidative stress injury, an SOD-specific Escherichia coli model and carrageenan-induced pleurisy. Free Radic Biol Med 46: 192-201, 2009.
16. Batinic-Haberle I, Ndengele MM, Cuzzocrea S, Reboucas JS, Spasojevic I, and Salvemini D. Lipophilicity is a critical parameter that dominates the efficacy of metalloporphyrins in blocking the development of morphine antinociceptive tolerance through peroxynitrite-mediated pathways. Free Radic Biol Med 46: 212-219, 2009.
17. Batinic-Haberle I, Rajic Z, Tovmasyan A, Reboucas JS, Ye X, Leong KW, Dewhirst MW, Vujaskovic Z, Benov L, and Spasojevic I. Diverse functions of cationic Mn(III) Nsubstituted pyridylporphyrins, recognized as SOD mimics. Free Radic Biol Med 51: 1035-1053, 2011.
18. Batinic-Haberle I, Reboucas JS, and Spasojevic I. Superoxide dismutase mimics: Chemistry, pharmacology, and therapeutic potential. Antioxid Redox Signal 13: 877-918, 2010.
19. - dismutation. J Chem Soc Dalton Trans 2689-2696, 2002.
20. Batinic-Haberle I, Spasojevic I, Tse HM, Tovmasyan A, Rajic Z, St Clair DK, Vujaskovic Z, Dewhirst MW, and Piganelli JD. Design of Mn porphyrins for treating oxidative stress injuries and their redox-based regulation of cellular transcriptional activities. Amino Acids 42: 95-113, 2012.
21. Batinic-Haberle I, Tovmasyan A, Roberts ERH, Vujakovic Z, Leong KW, and Spasojevic I. SOD therapeutics: latest insights into their structure-activity relationships and impact on the cellular redox-based pathways. Antioxid Redox Signal 20: 2372-2415, 2014.
22. Beauchamp C and Fridovich I. Superoxide dismutase: improved assays and an assay applicable to acrylamide gels. Anal Biochem 44: 276-287, 1971.
23. Beckman JS, Estevez AG, Crow JP, and Barbeito L. Superoxide dismutase and the death of motoneurons in ALS. Trends Neurosci 24: S15-S20, 2001.
24. Benatar M. Lost in translation: treatment trials in the SOD1 mouse and in human ALS. Neurobiol Dis 26: 1-13, 2007.
25. Bilbey DL, Salem H, and Grossman MH. The anatomical basis of the Straub phenomenon. Br J Pharmacol Chemother 15: 540-543, 1960.
26. Blesa J, Phani S, Jackson-Lewis V, and Przedborski S. Classic and new animal models of Parkinson's disease. J Biomed Biotechnol 2012: 845618, 2012.
27. Bove J and Perier C. Neurotoxin-based models of Parkinson's disease. Neuroscience 211: 51-76, 2012.
28. Breslin K and Agrawal D. The use of methylprednisolone in acute spinal cord injury: a review of the evidence, controversies, and recommendations. Pediatr Emerg Care 28: 1238-1245, 2012.
29. Brown GC and Bal-Price A. Inflammatory neurodegeneration mediated by nitric oxide, glutamate, and mitochondria. Mol Neurobiol 27: 325-355, 2003.
30. Bruns IR, Chhum S, Dinh AT, Doerr H, Dunn NR, Ly YT, Mitman CL, Rickards HD, Sol C, Wan EW, and Raffa RB. A potential novel strategy to separate therapeutic- and sideeffects that are mediated via the same receptor: betaarrestin2/G-protein coupling antagonists. J Clin Pharm Ther 31: 119-128, 2006.
31. Caner B, Hou J, Altay O, Fuj M, 2nd, and Zhang JH. Transition of research focus from vasospasm to early brain injury after subarachnoid hemorrhage. J Neurochem 123 Suppl 2: 12-21, 2012.
32. Castello PR, Drechsel DA, Day BJ, and Patel M. Inhibition of mitochondrial hydrogen peroxide production by lipophilic metalloporphyrins. J Pharmacol Exp Ther 324: 970-976, 2008.
33. Cerchiari EL, Hoel TM, Safar P, and Sclabassi RJ. Protective effects of combined superoxide dismutase and deferoxamine on recovery of cerebral blood flow and function after cardiac arrest in dogs. Stroke 18: 869-878, 1987.
34. Chan PH, Longar S, and Fishman RA. Protective effects of liposome-entrapped superoxide dismutase on posttraumatic brain edema. Ann Neurol 21: 540-547, 1987.
35. Chen H, Yoshioka H, Kim GS, Jung JE, Okami N, Sakata H, Maier CM, Narasimhan P, Goeders CE, and Chan PH. Oxidative stress in ischemic brain damage: mechanisms of cell death and potential molecular targets for neuroprotection. Antioxid Redox Signal 14: 1505-1517, 2011.
36. Chen P, Chen Z, Li A, Lou XC, Wu XK, Zhao CJ, Wang SL, and Liang LP. Catalytic metalloporphyrin protects against paraquat neurotoxicity in vivo. Biomed Environ Sci 21: 233-238, 2008.
37. Chen P, Li A, Zhang M, He M, Chen Z, Wu X, Zhao C, Wang S, and Liang L. Protective effects of a new metalloporphyrin on paraquat-induced oxidative stress and apoptosis in N27 cells. Acta Biochim Biophys Sin (Shanghai) 40: 125-132, 2008.
38. Chen SD, Chang AY, and Chuang YC. The potential role of mitochondrial dysfunction in seizure-associated cell death in the hippocampus and epileptogenesis. J Bioenerg Biomembr 42: 461-465, 2010.
39. Chen Z, Muscoli C, Doyle T, Bryant L, Cuzzocrea S, Mollace V, Mastroianni R, Masini E, and Salvemini D. NMDAreceptor activation and nitroxidative regulation of the glutamatergic pathway during nociceptive processing. Pain 149: 100-106, 2010.
40. Choi JI, Koehrn FJ, and Sorkin LS. Carrageenan induced phosphorylation of Akt is dependent on neurokinin-1 expressing neurons in the superficial dorsal horn. Mol Pain 8: 4, 2012.
41. Coderre TJ. The role of excitatory amino acid receptors and intracellular messengers in persistent nociception after tissue injury in rats. Mol Neurobiol 7: 229-246, 1993.
42. Cole DJ, Drummond JC, Shapiro HM, and Zornow MH. Influence of hypotension and hypotensive technique on the area of profound reduction in cerebral blood flow during focal cerebral ischaemia in the rat. Br J Anaesth 64: 498-502, 1990.
43. Crow JP. Manganese and iron porphyrins catalyze peroxynitrite decomposition and simultaneously increase nitration and oxidant yield: implications for their use as peroxynitrite scavengers in vivo. Arch Biochem Biophys 371: 41-52, 1999.
44. Crow JP. Catalytic antioxidants to treat amyotropic lateral sclerosis. Expert Opin Investig Drugs 15: 1383-1393, 2006.
45. Crow JP, Calingasan NY, Chen J, Hill JL, and Beal MF. Manganese porphyrin given at symptom onset markedly extends survival of ALS mice. Ann Neurol 58: 258-265, 2005.
46. Dang VC and Christie MJ. Mechanisms of rapid opioid receptor desensitization, resensitization and tolerance in brain neurons. Br J Pharmacol 165: 1704-1716, 2012.
47. Day BJ, Shawen S, Liochev SI, and Crapo JD. A metalloporphyrin superoxide dismutase mimetic protects against paraquat-induced endothelial cell injury, in vitro. J Pharmacol Exp Ther 275: 1227-1232, 1995.
48. Dehouck MP, Cecchelli R, Richard Green A, Renftel M, and Lundquist S. In vitro blood-brain barrier permeability and cerebral endothelial cell uptake of the neuroprotective nitrone compound NXY-059 in normoxic, hypoxic and ischemic conditions. Brain Res 955: 229-235, 2002.
49. Deng HX, Hentati A, Tainer JA, Iqbal Z, Cayabyab A, Hung WY, Getzoff ED, Hu P, Herzfeldt B, Roos RP, et al. Amyotrophic lateral sclerosis and structural defects in Cu, Zn superoxide dismutase. Science 261: 1047-1051, 1993.
50. Dexter DT, Carter CJ, Wells FR, Javoy-Agid F, Agid Y, Lees A, Jenner P, and Marsden CD. Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease. J Neurochem 52: 381-389, 1989.
51. Doyle T, Bryant L, Batinic-Haberle I, Little J, Cuzzocrea S, Masini E, Spasojevic I, and Salvemini D. Supraspinal inactivation of mitochondrial superoxide dismutase is a source of peroxynitrite in the development of morphine antinociceptive tolerance. Neuroscience 164: 702-710, 2009.
52. Doyle T, Bryant L, Muscoli C, Cuzzocrea S, Esposito E, Chen Z, and Salvemini D. Spinal NADPH oxidase is a source of superoxide in the development of morphine-induced hyperalgesia and antinociceptive tolerance. Neurosci Lett 483: 85-89, 2010.
53. Doyle T, Finley A, Chen Z, and Salvemini D. Role for peroxynitrite in sphingosine-1-phosphate-induced hyperalgesia in rats. Pain 152: 643-648, 2011.
54. Drel VR, Pacher P, Vareniuk I, Pavlov I, Ilnytska O, Lyzogubov VV, Tibrewala J, Groves JT, and Obrosova IG. A peroxynitrite decomposition catalyst counteracts sensory neuropathy in streptozotocin-diabetic mice. Eur J Pharmacol 569: 48-58, 2007.
55. Drobyshevsky A, Luo K, Derrick M, Yu L, Du H, Prasad PV, Vasquez-Vivar J, Batinic-Haberle I, and Tan S. Motor deficits are triggered by reperfusion-reoxygenation injury as diagnosed by MRI and by a mechanism involving oxidants. J Neurosci 32: 5500-5509, 2012.
56. Echlin F. Experimental vasospasm, acute and chronic, due to blood in the subarachnoid space. J Neurosurg 35: 646-656, 1971.
57. Epstein CJ, Avraham KB, Lovett M, Smith S, Elroy-Stein O, Rotman G, Bry C, and Groner Y. Transgenic mice with increased Cu/Zn-superoxide dismutase activity: animal model of dosage effects in Down syndrome. Proc Natl Acad Sci U S A 84: 8044-8048, 1987.
58. Estevez AG, Crow JP, Sampson JB, Reiter C, Zhuang Y, Richardson GJ, Tarpey MM, Barbeito L, and Beckman JS. Induction of nitric oxide-dependent apoptosis in motor neurons by zinc-deficient superoxide dismutase. Science 286: 2498-2500, 1999.
59. Faulkner KM, Liochev SI, and Fridovich I. Stable Mn(III) porphyrins mimic superoxide dismutase in vitro and substitute for it in vivo. J Biol Chem 269: 23471-23476, 1994.
60. Ferrer-Sueta G, Ruiz-Ramirez L, and Radi R. Ternary copper complexes and manganese (III) tetrakis(4-benzoic acid) porphyrin catalyze peroxynitrite- dependent nitration of aromatics. Chem Res Toxicol 10: 1338-1344, 1997.
61. Ferrer-Sueta G, Vitturi D, Batinic-Haberle I, Fridovich I, Goldstein S, Czapski G, and Radi R. Reactions of manganese porphyrins with peroxynitrite and carbonate radical anion. J Biol Chem 278: 27432-27438, 2003.
62. Flamm ES, Demopoulos HB, Seligman ML, Poser RG, and Ransohoff J. Free radicals in cerebral ischemia. Stroke 9: 445-447, 1978.
63. Folbergrova J, Haugvicova R, and Mares P. Behavioral and metabolic changes in immature rats during seizures induced by homocysteic acid: the protective effect of NMDA and non-NMDA receptor antagonists. Exp Neurol 161: 336-345, 2000.
64. Folbergrova J, Otahal J, and Druga R. Brain superoxide anion formation in immature rats during seizures: protection by selected compounds. Exp Neurol 233: 421-429, 2012.
65. Forsman M, Fleischer JE, Milde JH, Steen PA, and Michenfelder JD. Superoxide dismutase and catalase failed to improve neurologic outcome after complete cerebral ischemia in the dog. Acta Anaesthesiol Scand Suppl 32: 152-155, 1988.
66. Gardner PR and Fridovich I. Superoxide sensitivity of the Escherichia coli aconitase. J Biol Chem 266: 19328-19333, 1991.
67. Gardner PR and Fridovich I. Inactivation-reactivation of aconitase in Escherichia coli. A sensitive measure of superoxide radical. J Biol Chem 267: 8757-8763, 1992.
68. Genovese T, Mazzon E, Esposito E, Di Paola R, Murthy K, Neville L, Bramanti P, and Cuzzocrea S. Effects of a metalloporphyrinic peroxynitrite decomposition catalyst, ww- 85, in a mouse model of spinal cord injury. Free Radic Res 43: 631-645, 2009.
69. Genovese T, Mazzon E, Esposito E, Muia C, Di Paola R, Bramanti P, and Cuzzocrea S. Beneficial effects of FeTSPP, a peroxynitrite decomposition catalyst, in a mouse model of spinal cord injury. Free Radic Biol Med 43: 763-780, 2007.
70. Gurney ME, Pu H, Chiu AY, Dal Canto MC, Polchow CY, Alexander DD, Caliendo J, Hentati A, Kwon YW, Deng HX, et al. Motor neuron degeneration in mice that express a human Cu, Zn superoxide dismutase mutation. Science 264: 1772-1775, 1994.
71. Gushchin IS, Petyaev IM, and Tsinkalovsky OR. Kinetics of oxygen metabolism indices in the course of histamine secretion from rat mast cells. Agents Actions 30: 85-88, 1990.
72. Hachmeister JE, Valluru L, Bao F, and Liu D. Mn (III) tetrakis (4-benzoic acid) porphyrin administered into the intrathecal space reduces oxidative damage and neuron death after spinal cord injury: a comparison with methylprednisolone. J Neurotrauma 23: 1766-1778, 2006.
73. Haley JE, Dickenson AH, and Schachter M. Electrophysiological evidence for a role of nitric oxide in prolonged chemical nociception in the rat. Neuropharmacology 31: 251-258, 1992.
74. Hall ED, Vaishnav RA, and Mustafa AG. Antioxidant therapies for traumatic brain injury. Neurotherapeutics 7: 51-61, 2010.
75. Hamm RJ, Temple MD, Pike BR, and Ellis EF. The effect of postinjury administration of polyethylene glycolconjugated superoxide dismutase (pegorgotein, Dismutec) or lidocaine on behavioral function following fluidpercussion brain injury in rats. J Neurotrauma 13: 325-332, 1996.
76. Hensley K, Mhatre M, Mou S, Pye QN, Stewart C, West M, and Williamson KS. On the relation of oxidative stress to neuroinflammation: lessons learned from the G93A-SOD1 mouse model of amyotrophic lateral sclerosis. Antioxid Redox Signal 8: 2075-2087, 2006.
77. Hexum TD and Fried R. Effects of superoxide radicals on transport (Na+ K) adenosine triphosphatase and protection by superoxide dismutase. Neurochem Res 4: 73-82, 1979.
78. Howland DS, Liu J, She Y, Goad B, Maragakis NJ, Kim B, Erickson J, Kulik J, DeVito L, Psaltis G, DeGennaro LJ, Cleveland DW, and Rothstein JD. Focal loss of the glutamate transporter EAAT2 in a transgenic rat model of SOD1 mutant-mediated amyotrophic lateral sclerosis (ALS). Proc Natl Acad Sci U S A 99: 1604-1609, 2002.
79. Huang HF, Guo F, Cao YZ, Shi W, and Xia Q. Neuroprotection by manganese superoxide dismutase (MnSOD) mimics: Antioxidant effect and oxidative stress regulation in acute experimental stroke. CNS Neurosci Ther 18: 811-818, 2012.
80. Hurlbert RJ, Hadley MN, Walters BC, Aarabi B, Gelb DE, Rozzelle CJ, Ryken TC, and Theodor N. Pharmacological therapy for acute spinal cord injury. Neurosurgery 72: 93-105, 2013.
81. Iadecola C, Zhang F, Niwa K, Eckman C, Turner SK, Fischer E, Younkin S, Borchelt DR, Hsiao KK, and Carlson GA. SOD1 rescues cerebral endothelial dysfunction in mice overexpressing amyloid precursor protein. Nat Neurosci 2: 157-161, 1999.
82. Ibi M, Matsuno K, Matsumoto M, Sasaki M, Nakagawa T, Katsuyama M, Iwata K, Zhang J, Kaneko S, and Yabe-Nishimura C. Involvement of NOX1/NADPH oxidase in morphine-induced analgesia and tolerance. J Neurosci 31: 18094-18103, 2011.
83. Imam SZ, el-Yazal J, Newport GD, Itzhak Y, Cadet JL, Slikker W, Jr., and Ali SF. Methamphetamine-induced dopaminergic neurotoxicity: role of peroxynitrite and neuroprotective role of antioxidants and peroxynitrite decomposition catalysts. Ann N Y Acad Sci 939: 366-380, 2001.
84. Inaji M, Tomita H, Tone O, Tamaki M, Suzuki R, and Ohno K. Chronological changes of perihematomal edema of human intracerebral hematoma. Acta Neurochir Suppl 86: 445-448, 2003.
85. Ishigaki S, Niwa J, Ando Y, Yoshihara T, Sawada K, Doyu M, Yamamoto M, Kato K, Yotsumoto Y, and Sobue G. Differentially expressed genes in sporadic amyotrophic lateral sclerosis spinal cords-screening by molecular indexing and subsequent cDNA microarray analysis. FEBS Lett 531: 354-358, 2002.
86. Jaggi AS and Singh N. Therapeutic targets for the management of peripheral nerve injury-induced neuropathic pain. CNS Neurol Disord Drug Targets 10: 589-609, 2011.
87. This reference has been deleted.
88. Jaramillo MC, Briehl MM, Crapo JD, Batinic-Haberle I, and Tome ME. Manganese porphyrin, MnTE-2-PyP5+, acts as a pro-oxidant to potentiate glucocorticoid-induced apoptosis in lymphoma cells. Free Radic Biol Med 52: 1272-1284, 2012.
89. Jaramillo MC, Frye JB, Crapo JD, Briehl MM, and Tome ME. Increased manganese superoxide dismutase expression or treatment with manganese porphyrin potentiates dexamethasone-induced apoptosis in lymphoma cells. Cancer Res 69: 5450-5457, 2009.
90. Jaramillo MD, Briejl MM, and Tome ME. Manganese porphyrin glutathionylates the p65 subunit of NF-κB to potentiate glucocorticoid-induced apoptosis in lymphoma. Free Rad Biol Med 49: S63 (abstract), 2010.
91. Jarrett SG, Liang LP, Hellier JL, Staley KJ, and Patel M. Mitochondrial DNA damage and impaired base excision repair during epileptogenesis. Neurobiol Dis 30: 130-138, 2008.
92. Jensen MP and Riley DP. Peroxynitrite decomposition activity of iron porphyrin complexes. Inorg Chem 41: 4788-4797, 2002.
93. Kalivendi SV, Kotamraju S, Cunningham S, Shang T, Hillard CJ, and Kalyanaraman B. 1-Methyl-4-phenylpyridinium (MPP+)-induced apoptosis and mitochondrial oxidant generation: role of transferrin-receptor-dependent iron and hydrogen peroxide. Biochem J 371: 151-164, 2003.
94. Kang BT, Leoni RF, Kim DE, and Silva AC. Phenylephrine-induced hypertension during transient middle cerebral artery occlusion alleviates ischemic brain injury in spontaneously hypertensive rats. Brain Res 1477: 83-91, 2012.
95. Katsuki H. Exploring neuroprotective drug therapies for intracerebral hemorrhage. J Pharmacol Sci 114: 366-378, 2010.
96. Kazui S, Minematsu K, Yamamoto H, Sawada T, and Yamaguchi T. Predisposing factors to enlargement of spontaneous intracerebral hematoma. Stroke 28: 2370-2375, 1997.
97. Keynes RG and Garthwaite J. Nitric oxide and its role in ischaemic brain injury. Curr Mol Med 4: 179-191, 2004.
98. Khattab MM. TEMPOL, a membrane-permeable radical scavenger, attenuates peroxynitrite- and superoxide anionenhanced carrageenan-induced paw edema and hyperalgesia: a key role for superoxide anion. Eur J Pharmacol 548: 167-173, 2006.
99. Kilgannon JH, Jones AE, Parrillo JE, Dellinger RP, Milcarek B, Hunter K, Shapiro NI, and Trzeciak S. Relationship between supranormal oxygen tension and outcome after resuscitation from cardiac arrest. Circulation 123: 2717-2722, 2011.
100. Kim HY, Wang J, Lu Y, Chung JM, and Chung K. Superoxide signaling in pain is independent of nitric oxide signaling. Neuroreport 20: 1424-1428, 2009.
101. Kinouchi H, Epstein CJ, Mizui T, Carlson E, Chen SF, and Chan PH. Attenuation of focal cerebral ischemic injury in transgenic mice overexpressing CuZn superoxide dismutase. Proc Natl Acad Sci U S A 88: 11158-11162, 1991.
102. Kirsh KL and Fishman SM. Multimodal approaches to optimize outcomes of chronic opioid therapy in the management of chronic pain. Pain Med 12 Suppl 1: S1-S11, 2011.
103. Kos I, Benov L, Spasojevic I, Reboucas JS, and Batinic-Haberle I. High lipophilicity of meta Mn(III) Nalkylpyridylporphyrin-based superoxide dismutase mimics compensates for their lower antioxidant potency and makes them as effective as ortho analogues in protecting superoxide dismutase-deficient Escherichia coli. J Med Chem 52: 7868-7872, 2009.
104. Kos I, Reboucas JS, DeFreitas-Silva G, Salvemini D, Vujaskovic Z, Dewhirst MW, Spasojevic I, and Batinic-Haberle I. Lipophilicity of potent porphyrin-based antioxidants: comparison of ortho and meta isomers of Mn(III) N-alkylpyridylporphyrins. Free Radic Biol Med 47: 72-78, 2009.
105. Kurtikyan TS, Gulyan GM, Martirosyan GG, Lim MD, and Ford PC. Reactions of nitrogen oxides with heme models. Spectral and kinetic study of nitric oxide reactions with solid and solute Fe(III)(TPP)(NO3). J Am Chem Soc 127: 6216-6224, 2005.
106. Lebovitz RM, Zhang H, Vogel H, Cartwright J, Jr., Dionne L, Lu N, Huang S, and Matzuk MM. Neurodegeneration, myocardial injury, and perinatal death in mitochondrial superoxide dismutase-deficient mice. Proc Natl Acad Sci U S A 93: 9782-9787, 1996.
107. Lee BI, Chan PH, and Kim GW. Metalloporphyrin-based superoxide dismutase mimic attenuates the nuclear translocation of apoptosis-inducing factor and the subsequent DNA fragmentation after permanent focal cerebral ischemia in mice. Stroke 36: 2712-2717, 2005.
108. Lee JY, Keep RF, He Y, Sagher O, Hua Y, and Xi G. Hemoglobin and iron handling in brain after subarachnoid hemorrhage and the effect of deferoxamine on early brain injury. J Cereb Blood Flow Metab 30: 1793-1803, 2010.
109. Leinenweber SB, Sheng H, Lynch JR, Wang H, Batinic-Haberle I, Laskowitz DT, Crapo JD, Pearlstein RD, and Warner DS. Effects of a manganese (III) porphyrin catalytic antioxidant in a mouse closed head injury model. Eur J Pharmacol 531: 126-132, 2006.
110. Leski ML, Bao F, Wu L, Qian H, Sun D, and Liu D. Protein and DNA oxidation in spinal injury: neurofilaments-an oxidation target. Free Radic Biol Med 30: 613-624, 2001.
111. Liang LP, Ho YS, and Patel M. Mitochondrial superoxide production in kainate-induced hippocampal damage. Neuroscience 101: 563-570, 2000.
112. Liang LP, Huang J, Fulton R, Day BJ, and Patel M. An orally active catalytic metalloporphyrin protects against 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine neurotoxicity in vivo. J Neurosci 27: 4326-4333, 2007.
113. Liang LP, Waldbaum S, Rowley S, Huang TT, Day BJ, and Patel M. Mitochondrial oxidative stress and epilepsy in SOD2 deficient mice: attenuation by a lipophilic metalloporphyrin. Neurobiol Dis 45: 1068-1076, 2012.
114. Lin S, Yin Q, Zhong Q, Lv FL, Zhou Y, Li JQ, Wang JZ, Su BY, and Yang QW. Heme activates TLR4-mediated inflammatory injury via MyD88/TRIF signaling pathway in intracerebral hemorrhage. J Neuroinflammation 9: 46, 2012.
115. Ling X and Liu D. Temporal and spatial profiles of cell loss after spinal cord injury: Reduction by a metalloporphyrin. J Neurosci Res 85: 2175-2185, 2007.
116. Little JW, Doyle T, and Salvemini D. Reactive nitroxidative species and nociceptive processing: determining the roles for nitric oxide, superoxide, and peroxynitrite in pain. Amino Acids 42: 75-94, 2012.
117. Liu D, Bao F, Prough DS, and Dewitt DS. Peroxynitrite generated at the level produced by spinal cord injury induces peroxidation of membrane phospholipids in normal rat cord: reduction by a metalloporphyrin. J Neurotrauma 22: 1123-1133, 2005.
118. Liu D, Ling X, Wen J, and Liu J. The role of reactive nitrogen species in secondary spinal cord injury: formation of nitric oxide, peroxynitrite, and nitrated protein. J Neurochem 75: 2144-2154, 2000.
119. Liu D, Shan Y, Valluru L, and Bao F. Mn (III) tetrakis (4-benzoic acid) porphyrin scavenges reactive species, reduces oxidative stress, and improves functional recovery after experimental spinal cord injury in rats: comparison with methylprednisolone. BMC Neurosci 14: 23, 2013.
120. Liu TH, Beckman JS, Freeman BA, Hogan EL, and Hsu CY. Polyethylene glycol-conjugated superoxide dismutase and catalase reduce ischemic brain injury. Am J Physiol 256: H589-H593, 1989.
121. Luo J, Li N, Paul Robinson J, and Shi R. Detection of reactive oxygen species by flow cytometry after spinal cord injury. J Neurosci Methods 120: 105-112, 2002.
122. Lyden PD, Shuaib A, Lees KR, Davalos A, Davis SM, Diener HC, Grotta JC, Ashwood TJ, Hardemark HG, Svensson HH, Rodichok L, Wasiewski WW, and Ahlberg G. Safety and tolerability of NXY-059 for acute intracerebral hemorrhage: the CHANT Trial. Stroke 38: 2262-2269, 2007.
123. Lynn S, Huang EJ, Elchuri S, Naeemuddin M, Nishinaka Y, Yodoi J, Ferriero DM, Epstein CJ, and Huang TT. Selective neuronal vulnerability and inadequate stress response in superoxide dismutase mutant mice. Free Radic Biol Med 38: 817-828, 2005.
124. Ma T, Hoeffer CA, Wong H, Massaad CA, Zhou P, Iadecola C, Murphy MP, Pautler RG, and Klann E. Amyloid betainduced impairments in hippocampal synaptic plasticity are rescued by decreasing mitochondrial superoxide. J Neurosci 31: 5589-5595, 2011.
125. Machelska H, Ziolkowska B, Mika J, Przewlocka B, and Przewlocki R. Chronic morphine increases biosynthesis of nitric oxide synthase in the rat spinal cord. Neuroreport 8: 2743-2747, 1997.
126. Mackensen GB, Patel M, Sheng H, Calvi CL, Batinic-Haberle I, Day BJ, Liang LP, Fridovich I, Crapo JD, Pearlstein RD, and Warner DS. Neuroprotection from delayed postischemic administration of a metalloporphyrin catalytic antioxidant. J Neurosci 21: 4582-4592, 2001.
127. Mann PJ and Quastel JH. Toxic effects of oxygen and of hydrogen peroxide on brain metabolism. Biochem J 40: 139-144, 1946.
128. McConeghy KW, Hatton J, Hughes L, and Cook AM. A review of neuroprotection pharmacology and therapies in patients with acute traumatic brain injury. CNS Drugs 26: 613-636, 2012.
129. McCord JM and Fridovich I. The utility of superoxide dismutase in studying free radical reactions. I. Radicals generated by the interaction of sulfite, dimethyl sulfoxide, and oxygen. J Biol Chem 244: 6056-6063, 1969.
130. Melov S, Doctrow SR, Schneider JA, Haberson J, Patel M, Coskun PE, Huffman K, Wallace DC, and Malfroy B. Lifespan extension and rescue of spongiform encephalopathy in superoxide dismutase 2 nullizygous mice treated with superoxide dismutase-catalase mimetics. J Neurosci 21: 8348-8353, 2001.
131. Melov S, Schneider JA, Day BJ, Hinerfeld D, Coskun P, Mirra SS, Crapo JD, and Wallace DC. A novel neurological phenotype in mice lacking mitochondrial manganese superoxide dismutase. Nat Genet 18: 159-163, 1998.
132. Menon B, Ramalingam K, and Kumar RV. Oxidative stress in patients with epilepsy is independent of antiepileptic drugs. Seizure 21: 780-784, 2012.
133. Ment LR, Stewart WB, and Duncan CC. Beagle puppy model of intraventricular hemorrhage. Effect of superoxide dismutase on cerebral blood flow and prostaglandins. J Neurosurg 62: 563-569, 1985.
134. Mi K and Johnson GV. The role of tau phosphorylation in the pathogenesis of Alzheimer's disease. Curr Alzheimer Res 3: 449-463, 2006.
135. Miljkovic JL, Kenkel I, Ivanovic-Burmazovic I, Filipovic MR. Generation of HNO and HSNO from nitrite by heme-ironcatalyzed metabolism with H2S. Angew Chem Int Ed Engl 2013 [Epub ahead of print]; DOI: 10.1002/anie.201305669.
136. Miller AF. Superoxide dismutases: ancient enzymes and new insights. FEBS Lett 586: 585-595, 2012.
137. Miriyala S, Spasojevic I, Tovmasyan A, Salvemini D, Vujaskovic Z, St Clair D, and Batinic-Haberle I. Manganese superoxide dismutase, MnSOD and its mimics. Biochim Biophys Acta 1822: 794-814, 2012.
138. Misko TP, Highkin MK, Veenhuizen AW, Manning PT, Stern MK, Currie MG, and Salvemini D. Characterization of the cytoprotective action of peroxynitrite decomposition catalysts. J Biol Chem 273: 15646-15653, 1998.
139. Muizelaar JP, Marmarou A, Young HF, Choi SC, Wolf A, Schneider RL, and Kontos HA. Improving the outcome of severe head injury with the oxygen radical scavenger polyethylene glycol-conjugated superoxide dismutase: a phase II trial. J Neurosurg 78: 375-382, 1993.
140. Muscoli C, Cuzzocrea S, Ndengele MM, Mollace V, Porreca F, Fabrizi F, Esposito E, Masini E, Matuschak GM, and Salvemini D. Therapeutic manipulation of peroxynitrite attenuates the development of opiate-induced antinociceptive tolerance in mice. J Clin Invest 117: 3530-3539, 2007.
141. Navi BB, Kamel H, McCulloch CE, Nakagawa K, Naravetla B, Moheet AM, Wong C, Johnston SC, Hemphill JC, 3rd, and Smith WS. Accuracy of neurovascular fellows' prognostication of outcome after subarachnoid hemorrhage. Stroke 43: 702-707, 2012.
142. Ndengele MM, Cuzzocrea S, Esposito E, Mazzon E, Di Paola R, Matuschak GM, and Salvemini D. Cyclooxygenases 1 and 2 contribute to peroxynitrite-mediated inflammatory pain hypersensitivity. FASEB J 22: 3154-3164, 2008.
143. Negi G, Kumar A, and Sharma SS. Concurrent targeting of nitrosative stress-PARP pathway corrects functional, behavioral and biochemical deficits in experimental diabetic neuropathy. Biochem Biophys Res Commun 391: 102-106, 2010.
144. Nistico R, Mehdawy B, Piccirilli S, and Mercuri N. Paraquat- and rotenone-induced models of Parkinson's disease. Int J Immunopathol Pharmacol 24: 313-322, 2011.
145. Niwa K, Porter VA, Kazama K, Cornfield D, Carlson GA, and Iadecola C. A beta-peptides enhance vasoconstriction in cerebral circulation. Am J Physiol Heart Circ Physiol 281: H2417-H2424, 2001.
146. Obrosova IG, Mabley JG, Zsengeller Z, Charniauskaya T, Abatan OI, Groves JT, and Szabo C. Role for nitrosative stress in diabetic neuropathy: evidence from studies with a peroxynitrite decomposition catalyst. FASEB J 19: 401-403, 2005.
147. Olsen MK, Roberds SL, Ellerbrock BR, Fleck TJ, McKinley DK, and Gurney ME. Disease mechanisms revealed by transcription profiling in SOD1-G93A transgenic mouse spinal cord. Ann Neurol 50: 730-740, 2001.
148. Orrell RW. AEOL-10150 (Aeolus). Curr Opin Investig Drugs 7: 70-80, 2006.
149. Palomares SM, Gardner-Morse I, Sweet JG, and Cipolla MJ. Peroxynitrite decomposition with FeTMPyP improves plasma-induced vascular dysfunction and infarction during mild but not severe hyperglycemic stroke. J Cereb Blood Flow Metab 32: 1035-1045, 2012.
150. Pasternack RF, Banth A, Pasternack JM, and Johnson CS. Catalysis of the disproportionation of superoxide by metalloporphyrin III. J Inorg Biochem 15: 261-267, 1981.
151. Pasternak GW. When it comes to opiates, just say NO. J Clin Invest 117: 3185-3187, 2007.
152. Patel M, Day BJ, Crapo JD, Fridovich I, and McNamara JO. Requirement for superoxide in excitotoxic cell death. Neuron 16: 345-355, 1996.
153. Paynter DI, Moir RJ, and Underwood EJ. Changes in activity of the Cu-Zn superoxide dismutase enzyme in tissues of the rat with changes in dietary copper. J Nutr 109: 1570-1576, 1979.
154. Peluffo H, Shacka JJ, Ricart K, Bisig CG, Martinez-Palma L, Pritsch O, Kamaid A, Eiserich JP, Crow JP, Barbeito L, and Estevez AG. Induction of motor neuron apoptosis by free 3-nitro-L-tyrosine. J Neurochem 89: 602-612, 2004.
155. Petri S, Kiaei M, Kipiani K, Chen J, Calingasan NY, Crow JP, and Beal MF. Additive neuroprotective effects of a histone deacetylase inhibitor and a catalytic antioxidant in a transgenic mouse model of amyotrophic lateral sclerosis. Neurobiol Dis 22: 40-49, 2006.
156. Preiss M, Koblihova J, Netuka D, Bernardova L, Charvat F, and Benes V. Verbal memory capacity after treatment for ruptured intracranial aneurysm-the outcomes of three psychological tests:with in amonth, 1 year after and 5-7 years after treatment. Acta Neurochir (Wien) 154: 417-422, 2012.
157. Quagliaro L, Piconi L, Assaloni R, Da Ros R, Szabo C, and Ceriello A. Primary role of superoxide anion generation in the cascade of events leading to endothelial dysfunction and damage in high glucose treated HUVEC. Nutr Metab Cardiovasc Dis 17: 257-267, 2007.
158. Rajic Z, Tovmasyan A, Spasojevic I, Sheng H, Lu M, Li AM, Gralla EB, Warner DS, Benov L, and Batinic-Haberle I. A new SOD mimic, Mn(III) ortho N-butoxyethylpyridylporphyrin, combines superb potency and lipophilicity with low toxicity. Free Radic Biol Med 52: 1828-1834, 2012.
159. Rausaria S, Ghaffari MM, Kamadulski A, Rodgers K, Bryant L, Chen Z, Doyle T, Shaw MJ, Salvemini D, and Neumann WL. Retooling manganese(III) porphyrin-based peroxynitrite decomposition catalysts for selectivity and oral activity: a potential new strategy for treating chronic pain. J Med Chem 54: 8658-8669, 2011.
160. Reboucas JS, DeFreitas-Silva G, Spasojevic I, Idemori YM, Benov L, and Batinic-Haberle I. Impact of electrostatics in redox modulation of oxidative stress by Mn porphyrins: protection of SOD-deficient Escherichia coli via alternative mechanism where Mn porphyrin acts as a Mn carrier. Free Radic Biol Med 45: 201-210, 2008.
161. Reboucas JS, Spasojevic I, and Batinic-Haberle I. Pure manganese(III) 5,10,15,20-tetrakis(4-benzoic acid)porphyrin (MnTBAP) is not a superoxide dismutase mimic in aqueous systems: a case of structure-activity relationship as a watchdog mechanism in experimental therapeutics and biology. J Biol Inorg Chem 13: 289-302, 2008.
162. Reboucas JS, Spasojevic I, and Batinic-Haberle I. Quality of potent Mn porphyrin-based SOD mimics and peroxynitrite scavengers for pre-clinical mechanistic/therapeutic purposes. J Pharm Biomed Anal 48: 1046-1049, 2008.
163. Rhoads TW, Lopez NI, Zollinger DR, Morre JT, Arbogast BL, Maier CS, DeNoyer L, and Beckman JS. Measuringcopper and zinc superoxide dismutase from spinal cord tissue using electrospray mass spectrometry. Anal Biochem 415: 52-58, 2011.
164. Rosato RR, Kolla SS, Hock SK, Almenara JA, Patel A, Amin S, Atadja P, Fisher PB, Dent P, and Grant S. Histone deacetylase inhibitors activate NF-kappaB in human leukemia cells through an ATM/NEMO-related pathway. J Biol Chem 285: 10064-10077, 2010.
165. Ross AD, Sheng H, Warner DS, Piantadosi CA, Batinic-Haberle I, Day BJ, and Crapo JD. Hemodynamic effects of metalloporphyrin catalytic antioxidants: structure-activity relationships and species specificity. Free Radic Biol Med 33: 1657-1669, 2002.
166. Ryu H, Smith K, Camelo SI, Carreras I, Lee J, Iglesias AH, Dangond F, Cormier KA, Cudkowicz ME, Brown RH, Jr., and Ferrante RJ. Sodium phenylbutyrate prolongs survival and regulates expression of anti-apoptotic genes in transgenic amyotrophic lateral sclerosis mice. J Neurochem 93: 1087-1098, 2005.
167. Sabri M, Ai J, and Macdonald RL. Dissociation of vasospasm and secondary effects of experimental subarachnoid hemorrhage by clazosentan. Stroke 42: 1454-1460, 2011.
168. Sahawneh MA, Ricart KC, Roberts BR, Bomben VC, Basso M, Ye Y, Sahawneh J, Franco MC, Beckman JS, and Estevez AG. Cu, Zn-superoxide dismutase increases toxicity of mutant and zinc-deficient superoxide dismutase by enhancing protein stability. J Biol Chem 285: 33885-33897, 2010.
169. Salvemini D. Peroxynitrite and opiate antinociceptive tolerance: a painful reality. Arch Biochem Biophys 484: 238-244, 2009.
170. Salvemini D, Wang ZQ, Bourdon DM, Stern MK, Currie MG, and Manning PT. Evidence of peroxynitrite involvement in the carrageenan-induced rat paw edema. Eur J Pharmacol 303: 217-220, 1996.
171. Salvemini D, Wang ZQ, Stern MK, Currie MG, and Misko TP. Peroxynitrite decomposition catalysts: therapeutics for peroxynitrite-mediated pathology. Proc Natl Acad Sci U S A 95: 2659-2663, 1998.
172. Sampson JH, Raghavan R, Provenzale JM, Croteau D, Reardon DA, Coleman RE, Rodriguez Ponce I, Pastan I, Puri RK, and Pedain C. Induction of hyperintense signal on T2- weighted MR images correlates with infusion distribution from intracerebral convection-enhanced delivery of a tumortargeted cytotoxin. AJR Am J Roentgenol 188: 703-709, 2007.
173. Samra SK, Giordani B, Caveney AF, Clarke WR, Scott PA, Anderson S, Thompson BG, and Todd MM. Recovery of cognitive function after surgery for aneurysmal subarachnoid hemorrhage. Stroke 38: 1864-1872, 2007.
174. Santos RX, Correia SC, Zhu X, Lee HG, Petersen RB, Nunomura A, Smith MA, Perry G, and Moreira PI. Nuclear and mitochondrial DNA oxidation in Alzheimer's disease. Free Radic Res 46: 565-576, 2012.
175. Sastre M, Richardson JC, Gentleman SM, and Brooks DJ. Inflammatory risk factors and pathologies associated with Alzheimer's disease. Curr Alzheimer Res 8: 132-141, 2011.
176. Saugstad OD. Oxygen and retinopathy of prematurity. J Perinatol 26 Suppl 1: S46-S50; discussion S63-S64, 2006.
177. Schnellmann RG. Editor's note regarding "Protective mechanisms of a metalloporphyrinic peroxynitrite decomposition catalyst, WW85, in rat cardiac transplants". J Pharm Exp Ther 317: 462, 2006.
178. Schwartz ES, Kim HY, Wang J, Lee I, Klann E, Chung JM, and Chung K. Persistent pain is dependent on spinal mitochondrial antioxidant levels. J Neurosci 29: 159-168, 2009.
179. Sharma SS, Munusamy S, Thiyagarajan M, and Kaul CL. Neuroprotective effect of peroxynitrite decomposition catalyst and poly(adenosine diphosphate-ribose) polymerase inhibitor alone and in combination in rats with focal cerebral ischemia. J Neurosurg 101: 669-675, 2004.
180. Sheng H, Bart RD, Oury TD, Pearlstein RD, Crapo JD, and Warner DS. Mice overexpressing extracellular superoxide dismutase have increased resistance to focal cerebral ischemia. Neuroscience 88: 185-191, 1999.
181. Sheng H, Enghild JJ, Bowler R, Patel M, Batinic-Haberle I, Calvi CL, Day BJ, Pearlstein RD, Crapo JD, and Warner DS. Effects of metalloporphyrin catalytic antioxidants in experimental brain ischemia. Free Radic Biol Med 33: 947-961, 2002.
182. Sheng H, Spasojevic I, Tse HM, Jung JY, Hong J, Zhang Z, Piganelli JD, Batinic-Haberle I, and Warner DS. Neuroprotective efficacy from a lipophilic redox-modulating Mn(III) N-Hexylpyridylporphyrin, MnTnHex-2-PyP: rodent models of ischemic stroke and subarachnoid hemorrhage. J Pharmacol Exp Ther 338: 906-916, 2011.
183. Sheng H, Spasojevic I, Warner DS, and Batinic-Haberle I. Mouse spinal cord compression injury is ameliorated by intrathecal cationic manganese(III) porphyrin catalytic antioxidant therapy. Neurosci Lett 366: 220-225, 2004.
184. Sheng H, Yang W, Fukuda S, Tse HM, Paschen W, Johnson K, Batinic-Haberle I, Crapo JD, Pearlstein RD, Piganelli J, and Warner DS. Long-term neuroprotection from a potent redox-modulating metalloporphyrin in the rat. Free Radic Biol Med 47: 917-923, 2009.
185. Shin EJ, Jeong JH, Chung YH, Kim WK, Ko KH, Bach JH, Hong JS, Yoneda Y, and Kim HC. Role of oxidative stress in epileptic seizures. Neurochem Int 59: 122-137, 2011.
186. Siddique MM and Tan EK. Neurochemistry changes associated with mutations in familial Parkinson's disease. Curr Med Chem 17: 4378-4391, 2010.
187. Sies H. Oxidative stress: oxidants and antioxidants. Exp Physiol 82: 291-295, 1997.
188. Sompol P, Ittarat W, Tangpong J, Chen Y, Doubinskaia I, Batinic-Haberle I, Abdul HM, Butterfield DA, and St Clair DK. A neuronal model of Alzheimer's disease: an insight into the mechanisms of oxidative stress-mediated mitochondrial injury. Neuroscience 153: 120-130, 2008.
189. Spasojevic I, Batinic-Haberle I, and Fridovich I. Nitrosylation of manganese(II) tetrakis(N-ethylpyridinium-2-yl)porphyrin: a simple and sensitive spectrophotometric assay for nitric oxide. Nitric Oxide 4: 526-533, 2000.
190. Spasojevic I, Batinic-Haberle I, Reboucas JS, Idemori YM, and Fridovich I. Electrostatic contribution in the catalysis of O2*- dismutation by superoxide dismutase mimics. MnIIITE-2- PyP5 + versus MnIIIBr8T-2-PyP+. J Biol Chem 278: 6831-6837, 2003.
191. Spiegel S and Milstien S. Sphingosine-1-phosphate: an enigmatic signalling lipid. Nat Rev Mol Cell Biol 4: 397-407, 2003.
192. Stern MK, Jensen MP, and Kramer K. Peroxynitrite decomposition catalysts. J Am Chem Soc 118: 8735-8736, 1996.
193. Suofu Y, Clark J, Broderick J, Wagner KR, Tomsick T, Sa Y, and Lu A. Peroxynitrite decomposition catalyst prevents matrix metalloproteinase activation and neurovascular injury after prolonged cerebral ischemia in rats. J Neurochem 115: 1266-1276, 2010.
194. Szabo C, Ischiropoulos H, and Radi R. Peroxynitrite: biochemistry, pathophysiology and development of therapeutics. Nat Rev Drug Discov 6: 662-680, 2007.
195. Szabo C, Mabley JG, Moeller SM, Shimanovich R, Pacher P, Virag L, Soriano FG, Van Duzer JH, Williams W, Salzman AL, and Groves JT. Part I: pathogenetic role of peroxynitrite in the development of diabetes and diabetic vascular complications: studies with FP15, a novel potent peroxynitrite decomposition catalyst. Mol Med 8: 571-580, 2002.
196. Taha R and Blaise GA. Update on the pathogenesis of complex regional pain syndrome: role of oxidative stress. Can J Anaesth 59: 875-881, 2012.
197. Tam JH and Pasternak SH. Amyloid and Alzheimer's disease: inside and out. Can J Neurol Sci 39: 286-298, 2012.
198. Tauskela JS and Brunette E. Neuroprotection against staurosporine by metalloporphyrins independent of antioxidant capability. Neurosci Lett 466: 41-46, 2009.
199. Tauskela JS, Brunette E, O'Reilly N, Mealing G, Comas T, Gendron TF, Monette R, and Morley P. An alternative Ca2+ -dependent mechanism of neuroprotection by the metalloporphyrin class of superoxide dismutase mimetics. FASEB J 19: 1734-1736, 2005.
200. Thiyagarajan M, Kaul CL, and Sharma SS. Neuroprotective efficacy and therapeutic time window of peroxynitrite decomposition catalysts in focal cerebral ischemia in rats. Br J Pharmacol 142: 899-911, 2004.
201. Toda N, Kishioka S, Hatano Y, and Toda H. Modulation of opioid actions by nitric oxide signaling. Anesthesiology 110: 166-181, 2009.
202. Tong J, Yi X, Luxenhofer R, Banks WA, Jordan R, Zimmerman MC, and Kabanov AV. Conjugates of superoxide dismutase 1 with amphiphilic poly(2-oxazoline) block copolymers for enhanced brain delivery: Synthesis, characterization and evaluation in vitro and in vivo. Mol Pharm 10: 360-377, 2013.
203. Tovmasyan A, Weitner T, Reboucas JS, Sheng H, Warner DS, Spasojevic I, Benov L, and Batinc-Haberle I. Differential coordination demands in Fe vs Mn water soluble cationic metalloporphyrins translate into remarkably different aqueous redox chemistry and biology. Inorg Chem 52:5677-5691, 2013.
204. Tovmasyan A, Sheng H, Weitner T, Arulpragasam A, Lu M, Warner DS, Vukaskovic Z, Spasojevic I and Batinic-Haberle I. Design, mechanism of action, bioavailability and therapeutic effects of Mn porphyrin-based redox modulators. Med Princ Pract 22:103-30, 2013.
205. Tovmasyan A, Reboucas JS, and Benov L. Simple biological systems for assessing the activity of superoxide dismutase mimics. Antioxid Redox Signal 20: 2416-2436, 2014.
206. Trova MP, Gauuan PJ, Pechulis AD, Bubb SM, Bocckino SB, Crapo JD, and Day BJ. Superoxide dismutase mimetics. Part 2: synthesis and structure-activity relationship of glyoxylate- and glyoxamide-derived metalloporphyrins. Bioorg Med Chem 11: 2695-2707, 2003.
207. Tse HM, Milton MJ, and Piganelli JD. Mechanistic analysis of the immunomodulatory effects of a catalytic antioxidant on antigen-presenting cells: implication for their use in targeting oxidation-reduction reactions in innate immunity. Free Radic Biol Med 36: 233-247, 2004.
208. Ushio-Fukai M. Vascular signaling through G proteincoupled receptors: new concepts. Curr Opin Nephrol Hypertens 18: 153-159, 2009.
209. Vareniuk I, Pavlov IA, Drel VR, Lyzogubov VV, Ilnytska O, Bell SR, Tibrewala J, Groves JT, and Obrosova IG. Nitrosative stress and peripheral diabetic neuropathy in leptin-deficient (ob/ob) mice. Exp Neurol 205: 425-436, 2007.
210. Veronese FM, Caliceti P, Schiavon O, and Sergi M. Polyethylene glycol-superoxide dismutase, a conjugate in search of exploitation. Adv Drug Deliv Rev 54: 587-606, 2002.
211. Wagner KR. Modeling intracerebral hemorrhage: glutamate, nuclear factor-kappa B signaling and cytokines. Stroke 38: 753-758, 2007.
212. Waldbaum S and Patel M. Mitochondrial dysfunction and oxidative stress: a contributing link to acquired epilepsy? J Bioenerg Biomembr 42: 449-455, 2010.
213. Wang ZQ, Porreca F, Cuzzocrea S, Galen K, Lightfoot R, Masini E, Muscoli C, Mollace V, Ndengele M, Ischiropoulos H, and Salvemini D. A newly identified role for superoxide in inflammatory pain. J Pharmacol Exp Ther 309: 869-878, 2004.
214. Warner DS, Sheng H, and Batinic-Haberle I. Oxidants, antioxidants and the ischemic brain. J Exp Biol 207: 3221-3231, 2004.
215. Wei EP, Kontos HA, Dietrich WD, Povlishock JT, and Ellis EF. Inhibition by free radical scavengers and by cyclooxygenase inhibitors of pial arteriolar abnormalities from concussive brain injury in cats. Circ Res 48: 95-103, 1981.
216. Weitner T, Kos I, Sheng H, Tovmasyan A, Reboucas JS, Fan P, Warner DS, Vujaskovic Z, Batinc-Haberle I, and Spasojevic I. Comprehensive pharmacokinetic studies and oral bioavailability of two Mn porphyrin-based SOD mimics, MnTE-2-PyP5+ and MnTnHex-2-PyP5+. Free Rad Biol Med 58: 73-0, 2013.
217. Welch SP, Sim-Selley LJ, and Selley DE. Sphingosine-1- phosphate receptors as emerging targets for treatment of pain. Biochem Pharmacol 84: 1551-1562, 2012.
218. Westermaier T, Jauss A, Eriskat J, Kunze E, and Roosen K. Acute vasoconstriction: decrease and recovery of cerebral blood flow after various intensities of experimental subarachnoid hemorrhage in rats. J Neurosurg 110: 996-1002, 2009.
219. White BC, Nayini NR, Krause GS, Aust SD, March GG, Bicknell JS, and Goosmann M. Effect on biochemical markers of brain injury of therapy with deferoxamine or superoxide dismutase following cardiac arrest. Am J Emerg Med 6: 569-576, 1988.
220. Wu AS, Kiaei M, Aguirre N, Crow JP, Calingasan NY, Browne SE, and Beal MF. Iron porphyrin treatment extends survival in a transgenic animal model of amyotrophic lateral sclerosis. J Neurochem 85: 142-150, 2003.
221. Ye Y, Quijano C, Robinson KM, Ricart KC, Strayer AL, Sahawneh MA, Shacka JJ, Kirk M, Barnes S, Accavitti-Loper MA, Radi R, Beckman JS, and Estevez AG. Prevention of peroxynitrite-induced apoptosis of motor neurons and PC12 cells by tyrosine-containing peptides. J Biol Chem 282: 6324-6337, 2007.
222. Yeo JF, Ling SF, Tang N, and Ong WY. Antinociceptive effect of CNS peroxynitrite scavenger in a mouse model of orofacial pain. Exp Brain Res 184: 435-438, 2008.
223. Yoshida K, Burton GF, McKinney JS, Young H, and Ellis EF. Brain and tissue distribution of polyethylene glycolconjugated superoxide dismutase in rats. Stroke 23: 865-869, 1992.
224. Young B, Runge JW, Waxman KS, Harrington T, Wilberger J, Muizelaar JP, Boddy A, and Kupiec JW. Effects of pegorgotein on neurologic outcome of patients with severe head injury. A multicenter, randomized controlled trial. JAMA 276: 538-543, 1996.
225. Yu D, Neeley WL, Pritchard CD, Slotkin JR, Woodard EJ, Langer R, and Teng YD. Blockade of peroxynitrite-induced neural stem cell death in the acutely injured spinal cord by drug-releasing polymer. Stem Cells 27: 1212-1222, 2009.
226. Zhang J, Perry G, Smith MA, Robertson D, Olson SJ, Graham DG, and Montine TJ. Parkinson's disease is associated with oxidative damage to cytoplasmic DNA and RNA in substantia nigra neurons. Am J Pathol 154: 1423-1429, 1999.
227. Zhao MM, Xu MJ, Cai Y, Zhao G, Guan Y, Kong W, Tang C, and Wang X. Mitochondrial reactive oxygen species promote p65 nuclear translocation mediating highphosphate-induced vascular calcification in vitro and in vivo. Kidney Int 79: 1071-1079, 2011.
228. Zhou ML, Shi JX, Hang CH, Cheng HL, Qi XP, Mao L, Chen KF, and Yin HX. Potential contribution of nuclear factor-kappaB to cerebral vasospasm after experimental subarachnoid hemorrhage in rabbits. J Cereb Blood Flow Metab 27: 1583-1592, 2007.